$14.51
-1.34 (-8.45%)
Open$15.07
Previous Close$15.85
Day High$15.07
Day Low$14.50
52W High$42.12
52W Low$3.66
Volume—
Avg Volume3.4K
Market Cap19.45M
P/E Ratio—
EPS$-64.31
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-14.6% upside
Current
$14.51
$14.51
Target
$12.39
$12.39
$7.78
$12.39 avg
$16.73
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.59M | 4.05M | 3.58M |
| Net Income | -196,564 | -196,089 | -156,693 |
| Profit Margin | -4.3% | -4.8% | -4.4% |
| EBITDA | -265,994 | -241,454 | -219,779 |
| Free Cash Flow | -252,687 | -239,821 | -142,632 |
| Rev Growth | +16.2% | +0.5% | -3.6% |
| Debt/Equity | 1.06 | 0.93 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |